{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:06:09Z","timestamp":1786982769858,"version":"build-2736575974"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2017,5,23]],"date-time":"2017-05-23T00:00:00Z","timestamp":1495497600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100000961","name":"State Health Research Advisory Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000961","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1007\/s40265-017-0763-8","type":"journal-article","created":{"date-parts":[[2017,5,23]],"date-time":"2017-05-23T00:29:07Z","timestamp":1495499347000},"page":"1211-1219","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["A Retrospective Cohort Study of Birth Outcomes in Neonates Exposed to Naltrexone in Utero: A Comparison with Methadone-, Buprenorphine- and Non-opioid-Exposed Neonates"],"prefix":"10.1007","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0841-2216","authenticated-orcid":false,"given":"Erin","family":"Kelty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Hulse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,5,23]]},"reference":[{"key":"763_CR1","unstructured":"Center for substance abuse treatment. Medication-assisted treatment for opioid addiction in in Opioid treatment programs. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 2005, (Treatment Improvement Protocol (TIP) Series, No. 43). Medication-assisted treatment for Opioid addiction during pregnancy. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK64148\/ ."},{"issue":"2","key":"763_CR2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1080\/02791072.1991.10472236","volume":"23","author":"L Finnegan","year":"1991","unstructured":"Finnegan L. Treatment issues for opioid dependent women during the perinatal period. J Psychoact Drugs. 1991;23(2):191\u2013201.","journal-title":"J Psychoact Drugs"},{"key":"763_CR3","volume-title":"Guidelines for the identification and management of substance use and substance use disorders in pregnancy","author":"WHO","year":"2014","unstructured":"WHO. Guidelines for the identification and management of substance use and substance use disorders in pregnancy. Geneva: World Health Organisation; 2014."},{"issue":"1","key":"763_CR4","first-page":"80","volume":"29","author":"T Binder","year":"2008","unstructured":"Binder T, Vavrinkova B. Prospective randomised comparative study of the effect of buprenorphine, methadone and heroin on the course of pregnancy, birthweight of newborns, early postpartum adaptation and course of the neonatal abstinence syndrome (NAS) in women followed up in the outpatient department. Neuro Endocrinol Lett. 2008;29(1):80\u20136.","journal-title":"Neuro Endocrinol Lett"},{"key":"763_CR5","doi-asserted-by":"crossref","unstructured":"Patrick S, Schumacher R, Benneyworth B, Krans E, McAllister J, Davis M. Neonatal abstinence syndrome and associated health care expenditures: United States, 2000\u20132009. JAMA. 2012;307(18):1934\u201340.","DOI":"10.1001\/jama.2012.3951"},{"issue":"24","key":"763_CR6","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1056\/NEJMoa1005359","volume":"363","author":"HE Jones","year":"2010","unstructured":"Jones HE, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 2010;363(24):2320\u201331.","journal-title":"N Engl J Med"},{"issue":"2","key":"763_CR7","doi-asserted-by":"crossref","first-page":"e547","DOI":"10.1542\/peds.2013-3524","volume":"134","author":"P Kocherlakota","year":"2014","unstructured":"Kocherlakota P. Neonatal abstinence syndrome. Pediatrics. 2014;134(2):e547\u201361.","journal-title":"Pediatrics"},{"issue":"1","key":"763_CR8","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.0004-8666.2002.00104.x","volume":"42","author":"GK Hulse","year":"2002","unstructured":"Hulse GK, O\u2019Neill G. A possible role for implantable naltrexone in the management of the high-risk pregnant heroin user. Aust N Z J Obstet Gynaecol. 2002;42(1):104\u20135.","journal-title":"Aust N Z J Obstet Gynaecol"},{"issue":"2","key":"763_CR9","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ijgo.2003.10.001","volume":"85","author":"GK Hulse","year":"2004","unstructured":"Hulse GK, O\u2019Neil G, Arnold-Reed DE. Methadone maintenance vs. implantable naltrexone treatment in the pregnant heroin user. Int J Gynaecol Obstet. 2004;85(2):170\u20131.","journal-title":"Int J Gynaecol Obstet"},{"issue":"5","key":"763_CR10","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1046\/j.0004-8666.2003.00121.x","volume":"43","author":"GK Hulse","year":"2003","unstructured":"Hulse GK, et al. Naltrexone implant and blood naltrexone levels over pregnancy. Aust N Z J Obstet Gynaecol. 2003;43(5):386\u20138.","journal-title":"Aust N Z J Obstet Gynaecol"},{"issue":"5","key":"763_CR11","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.0004-8666.2002.548_14.x","volume":"42","author":"GK Hulse","year":"2002","unstructured":"Hulse GK, O\u2019Neil G. Using naltrexone implants in the management of the pregnant heroin user. Aust N Z J Obstet Gynaecol. 2002;42(5):102\u20136.","journal-title":"Aust N Z J Obstet Gynaecol"},{"issue":"4","key":"763_CR12","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1479-828X.2001.tb01322.x","volume":"41","author":"GK Hulse","year":"2001","unstructured":"Hulse GK, et al. Obstetric and neonatal outcomes associated with maternal naltrexone exposure. Aust N Z J Obstet Gynaecol. 2001;41(4):424\u20138.","journal-title":"Aust N Z J Obstet Gynaecol"},{"issue":"12","key":"763_CR13","doi-asserted-by":"crossref","first-page":"e52812","DOI":"10.1371\/journal.pone.0052812","volume":"7","author":"WO Farid","year":"2012","unstructured":"Farid WO, et al. Maternally administered sustained-released naltrexone in rats affects offpsring neurochemistry and behaviour in adulthood. PLoS One. 2012;7(12):e52812.","journal-title":"PLoS One"},{"issue":"2","key":"763_CR14","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1360-0443.2012.03914.x","volume":"108","author":"J White","year":"2013","unstructured":"White J. Blocking endogenous opioids during development-do we understand the consequences? Addiction. 2013;108(2):251\u20132.","journal-title":"Addiction"},{"issue":"2","key":"763_CR15","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1360-0443.2012.03811.x","volume":"108","author":"HE Jones","year":"2013","unstructured":"Jones HE, et al. Naltrexone in the treatment of opioid-dependent pregnant women: the case for a considered and measured approach to research. Addiction. 2013;108(2):233\u201347.","journal-title":"Addiction"},{"issue":"3","key":"763_CR16","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/0091-3057(94)00289-U","volume":"50","author":"GI Keshet","year":"1995","unstructured":"Keshet GI, Weinstock M. Maternal naltrexone prevents morphological and behavioral alterations induced in rats by prenatal stress. Pharmacol Biochem Behav. 1995;50(3):413\u20139.","journal-title":"Pharmacol Biochem Behav"},{"issue":"1","key":"763_CR17","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0091-3057(97)00419-X","volume":"59","author":"IS Zagon","year":"1998","unstructured":"Zagon IS, et al. Opioid receptor blockade throughout prenatal life confers long-term insensitivity to morphine and alters mu opioid receptors. Pharmacol Biochem Behav. 1998;59(1):201\u20137.","journal-title":"Pharmacol Biochem Behav"},{"issue":"4","key":"763_CR18","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0091-3057(97)00307-9","volume":"58","author":"PJ McLaughlin","year":"1997","unstructured":"McLaughlin PJ, et al. Opioid receptor blockade during prenatal life modifies postnatal behavioral development. Pharmacol Biochem Behav. 1997;58(4):1075\u201382.","journal-title":"Pharmacol Biochem Behav"},{"issue":"2","key":"763_CR19","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2174\/157015908784533842","volume":"6","author":"WO Farid","year":"2008","unstructured":"Farid WO, et al. The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data. Curr Neuropharmacol. 2008;6(2):125\u201350.","journal-title":"Curr Neuropharmacol"},{"issue":"1","key":"763_CR20","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.pnpbp.2007.06.007","volume":"32","author":"HTT Ngo","year":"2008","unstructured":"Ngo HTT, et al. Blood naltrexone levels over time following naltrexone implant. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(1):23\u20138.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"763_CR21","unstructured":"Bower C, et al., Report of the Western Australian register of developmental anomolies: 1980\u20132011. 2012. King Edward Memorial Hospital."},{"key":"763_CR22","volume-title":"Birth defects surveillance: a manual for programme managers","author":"WHO, CDC, ICBDSR","year":"2014","unstructured":"WHO, CDC, ICBDSR. Birth defects surveillance: a manual for programme managers. Geneva: World Health Organisation; 2014."},{"key":"763_CR23","doi-asserted-by":"crossref","first-page":"114","DOI":"10.5694\/j.1326-5377.1999.tb127678.x","volume":"170","author":"CL Roberts","year":"1999","unstructured":"Roberts CL, Lancaster PAL. Australian national birthweight percentiles by gestational age. Med J Aust. 1999;170:114\u20138.","journal-title":"Med J Aust"},{"issue":"2","key":"763_CR24","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ejogrb.2005.08.010","volume":"126","author":"O Fajemirokun-Odudeyi","year":"2006","unstructured":"Fajemirokun-Odudeyi O, et al. Pregnancy outcome in women who use opiates. Eur J Obstet Gynecol Reprod Biol. 2006;126(2):170\u20135.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"5","key":"763_CR25","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/j.1465-3362.2010.00176.x","volume":"29","author":"L Burns","year":"2010","unstructured":"Burns L, Conroy E, Mattick RP. Infant mortality among women on a methadone program during pregnancy. Drug Alcohol Rev. 2010;29(5):551\u20136.","journal-title":"Drug Alcohol Rev"},{"issue":"2","key":"763_CR26","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0378-3782(77)90017-2","volume":"1","author":"SR Kandall","year":"1977","unstructured":"Kandall SR, et al. The narcotic-dependent mother: fetal and neonatal consequences. Early Hum Dev. 1977;1(2):159\u201369.","journal-title":"Early Hum Dev"},{"issue":"5","key":"763_CR27","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/j.1471-0528.2008.02073.x","volume":"116","author":"C Dryden","year":"2009","unstructured":"Dryden C, et al. Maternal methadone use in pregnancy: factors associated with the development of neonatal abstinence syndrome and implications for healthcare resources. BJOG. 2009;116(5):665\u201371.","journal-title":"BJOG"},{"issue":"4","key":"763_CR28","doi-asserted-by":"crossref","first-page":"383","DOI":"10.3109\/00952998209002641","volume":"9","author":"B Stimmel","year":"1982","unstructured":"Stimmel B, et al. Fetal outcome in narcotic-dependent women: the importance of the type of maternal narcotic used. Am J Drug Alcohol Abuse. 1982;9(4):383\u201395.","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"23","key":"763_CR29","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJM197312062892303","volume":"289","author":"C Zelson","year":"1973","unstructured":"Zelson C, Lee SJ, Casalino M. Neonatal narcotic addiction. N Engl J Med. 1973;289(23):1216\u201320.","journal-title":"N Engl J Med"},{"key":"763_CR30","doi-asserted-by":"crossref","unstructured":"Zedler BK, et al. Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta-analysis of safety in the mother, fetus and child. Addiction, 2016.","DOI":"10.1111\/add.13462"},{"issue":"2","key":"763_CR31","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/ADM.0000000000000092","volume":"9","author":"MC Meyer","year":"2015","unstructured":"Meyer MC, et al. Methadone and buprenorphine for opioid dependence during pregnancy: a retrospective cohort study. J Addict Med. 2015;9(2):81\u20136.","journal-title":"J Addict Med"},{"issue":"10","key":"763_CR32","doi-asserted-by":"crossref","first-page":"e011774","DOI":"10.1136\/bmjopen-2016-011774","volume":"6","author":"NA Jumah","year":"2016","unstructured":"Jumah NA, et al. Observational study of the safety of buprenorphine\u00a0+\u00a0naloxone in pregnancy in a rural and remote population. BMJ Open. 2016;6(10):e011774.","journal-title":"BMJ Open"},{"key":"763_CR33","first-page":"89","volume":"10","author":"KE Wurst","year":"2016","unstructured":"Wurst KE, et al. A Swedish population-based study of adverse birth outcomes among pregnant women treated with buprenorphine or methadone: preliminary findings. Subst Abuse. 2016;10:89\u201397.","journal-title":"Subst Abuse"},{"issue":"3","key":"763_CR34","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S0031-9384(97)00007-3","volume":"62","author":"PJ McLaughlin","year":"1997","unstructured":"McLaughlin PJ, et al. Chronic exposure to the opioid antagonist naltrexone during pregnancy: maternal and offspring effects. Physiol Behav. 1997;62(3):501\u20138.","journal-title":"Physiol Behav"},{"issue":"5","key":"763_CR35","first-page":"663","volume":"65","author":"MS Kramer","year":"1987","unstructured":"Kramer MS. Determinants of low birth weight: methodological assessment and meta-analysis. Bull World Health Organ. 1987;65(5):663\u2013737.","journal-title":"Bull World Health Organ"},{"issue":"7726","key":"763_CR36","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(71)92250-1","volume":"2","author":"L Glass","year":"1971","unstructured":"Glass L, Rajegowda BK, Evans HE. Absence of respiratory distress syndrome in premature infants of heroin-addicted mothers. Lancet. 1971;2(7726):685\u20136.","journal-title":"Lancet"},{"issue":"1","key":"763_CR37","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.wombi.2010.07.001","volume":"24","author":"J Blandthorn","year":"2011","unstructured":"Blandthorn J, Forster DA, Love V. Neonatal and maternal outcomes following maternal use of buprenorphine or methadone during pregnancy: findings of a retrospective audit. Women Birth. 2011;24(1):32\u20139.","journal-title":"Women Birth"},{"issue":"4","key":"763_CR38","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/bdra.20658","volume":"88","author":"C Bower","year":"2010","unstructured":"Bower C, et al. Age at diagnosis of birth defects. Birth Defects Res A Clin Mol Teratol. 2010;88(4):251\u20135.","journal-title":"Birth Defects Res A Clin Mol Teratol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-017-0763-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-017-0763-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-017-0763-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T04:03:30Z","timestamp":1719201810000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-017-0763-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,23]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["763"],"URL":"https:\/\/doi.org\/10.1007\/s40265-017-0763-8","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727661031.793540541","asserted-by":"object"}]},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,23]]}}}